US Patent

US11504354 — Chlorinated tetralin compounds and pharmaceutical compositions

Formulation · Assigned to SpringWorks Therapeutics Inc · Expires 2042-07-08 · 16y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects chlorinated tetralin compounds and pharmaceutical compositions, specifically a formulation of nirogacestat hydrobromide.

USPTO Abstract

The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.

Drugs covered by this patent

nirogacestat-hydrobromide (NIROGACESTAT HYDROBROMIDE)

Patent Metadata

Patent number: US11504354
Jurisdiction: US
Classification: Formulation
Expires: 2042-07-08
Drug substance claim: No
Drug product claim: Yes
Assignee: SpringWorks Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.